Related Experiment Videos
Acute myeloid leukaemia in children
P B Langmuir1, R Aplenc, B J Lange
1The University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Best Practice & Research. Clinical Haematology
|May 18, 2001
Summary
Childhood acute myeloid leukaemia (AML) involves myeloid progenitor cell issues. Advances in treatment, including chemotherapy and bone marrow transplants, improve survival rates, with future research focusing on targeted therapies and risk stratification.
Area of Science:
- Pediatric Hematology Oncology
- Cancer Biology
Background:
- Acute myeloid leukaemia (AML) in children is a cancer of myeloid progenitor cells, marked by blocked differentiation and uncontrolled proliferation.
- Identified risk factors include environmental toxin exposure (ethanol, pesticides, topoisomerase II inhibitors), prior chemotherapy, genetic disorders (Down's syndrome, neurofibromatosis type I), and bone marrow failure syndromes (Fanconi anaemia, severe congenital neutropenia).
Purpose of the Study:
- To summarize the current understanding of childhood acute myeloid leukaemia (AML).
- To outline identified risk factors and current treatment outcomes.
- To suggest future directions for pediatric AML research and therapy.
Main Methods:
- This abstract summarizes existing knowledge on pediatric AML, drawing from identified risk factors and treatment outcomes.
- It reviews current therapeutic approaches and survival statistics.
- It discusses potential future advancements in the field.
Main Results:
- Current survival rates for pediatric AML approach 50% with intensified chemotherapy (e.g., high-dose Ara-C) and bone marrow transplantation.
- Improvements in supportive care have also contributed to better outcomes.
Conclusions:
- Future progress in pediatric AML treatment will depend on enhanced risk stratification for personalized treatment strategies.
- Targeted cytotoxic therapies hold promise for improving outcomes in children with AML.